| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Adalimumab |
| Brand | Humira® |
| Indication | In combination with methotrexate for polyarticular juvenile idiopathic arthritis in children and adolescents (4-17yrs) in patients who have had an inadequate response to DMARDs. Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate. |
| Assessment Process | |
| Rapid review commissioned | 20/05/2011 |
| Rapid review completed | 02/06/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended |
